BEVERLY HILLS, CA -- (MARKET WIRE) -- 10/18/2005 -- Amexdrug Corporation (OTC BB: AXRX), who recently announced the completion of the Dermagen Inc. acquisition, filed SEC Form 8-K which, among other things, confirmed the closure of the company's recent acquisition in a cash deal. According to terms of the agreement, Dermagen will now become an operating subsidiary of Amexdrug, adding a significant manufacturing component to Amexdrug's structure, as well as extensive expertise in numerous phases of private label contract packaging.
